Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation

Nuclear Medicine and Biology

Volumn 36, Issue 6, 2009, Pages 591-603

  Koumarianou, Eftychia ^a,b   Mikołajczak, Renata ^b   Pawlak, Dariusz ^b   Zikos, Xhristos ^a   Bouziotis, Pinelopi ^a   Garnuszek, Piotr ^c   Karczmarczyk, Urszula ^c   Maurin, Michał ^c   Archimandritis, Spyridon C ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Emitters; Bombesin analog; GRP analogs; Lutetium 177; Yttrium 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BOMBESIN[2-14]AMINE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID BOMBESIN[2-14]AMINE Y 90; DIAGNOSTIC AGENT; GASTRIN RELEASING PEPTIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; ISOTOPE LABELING; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BLOCKING;

ANIMALS; BIOLOGICAL TRANSPORT; BOMBESIN; CELL LINE, TUMOR; CELL SURVIVAL; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; LUTETIUM; MALE; MICE; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 67749088492     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.03.006     Document Type: Article

References (36)

1. Radioisotopes in Medicine. Nuclear Issues Briefing, Paper 26 (2004), Uranium Information Centre Ltd, Melbourne 1-8
2. Prevost G., Marmant C., Gunning M., and Thomas F. Therapeutic use and perspectives of synthetic peptides in oncology. Acta Oncol 32 No 2 (1993) 209-215
3. Hofland L.J., Visser-Wisselaar H.A., and Lamberts S.W. Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. J Biochem Pharm 50 No 3 (1995) 287-297
4. Dasgupta P. Somatostatin analogues. Multiple roles in cellular proliferation, neoplasia and angiogenesis. Pharm Ther 102 Is. 1 (2004) 61-85
5. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27 (2000) 273-282
6. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., and Fischler A. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316 (1985) 823-825
7. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24 4 (2003) 389-427
8. Carney D.N., Cuttitta F., Moody T.W., and Minna J.D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47 (1987) 821-825
9. Moody T.W., and Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci 52 (1993) 1161-1173
10. 99mTc-labeled bombesin-like peptides for early cancer detection. Anticancer Res 26 1A (2006) 435-438
11. 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells. Nucl Med Biol 30 (2003) 101-109
12. Heeg M.J., and Jurisson S.S. The role of inorganic chemistry in the development of radiometal agents for cancer therapy. Acc Chem Res 32 (1993) 1050-1060
13. Cutler C.S., Smith C.J., Ehrhardt G.J., Tyler T.T., Jurisson S.S., and Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm 15 6 (2000) 531-545
14. 131I. J Nucl Med 42 (2001) 967-974
15. Rogers B.E., Brechbiel M.W., Kirkman R.L., Clarkson M., and Buchsbaum D.J.D. In: Nicolini M. (Ed). "In vitro binding and internalization of an Indium-111 labeled bombesin derivative to cells expressing the gastrin releasing peptide receptor." Technetium, rhenium and other metals in chemistry and nuclear medicine (1999), SGE Editorial, Italy 519-525
16. 111In-DTPA0]octreotide in patients. Eur J Nucl Med 28 (2001) 1319-1325
17. Zhang H., Schumacher J., Waser B., Wild D., Eisenhut M., and Reubi J.C. DOTA-PESIN, a DOTA conjugate bombesin derivative designed for the treatment of bombesin receptor - positive tumours. Eur J Nucl Med Mol Imaging 34 (2007) 1198-1208
18. Cosentino U., Villa A., Pitea D., Moro G., Barone V., and Maiocchi A. Conformational characterization of lanthanide(III)-DOTA complexes by ab initio investigation in vacuo and in aqueous solution. J Am Chem Soc 1,124 17 (2002) 4901-4909
19. Aime S., Botta M., Fasano M., Marques M.P., Geraldes C.F., Pubanz D., et al. Conformational and coordination equilibria on DOTA complexes of lanthanide metal ions in aqueous solution studied by (1)H-NMR spectroscopy. Inorg Chem 36 10 (1997) 2059-2068
20. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med 30 (2003) 247-258
21. Li W.P., Ma D.S., Higginbotham C., Hoffman T., Ketring A.R., and Cutler C.S. Development of an in vitro model for assessing the in vivo stability of lanthanide chelates. Nucl Med Biol 28 2 (2001) 145-154
22. Toth E., Brucher E., Lazar I., and Toth I. Kinetics of formation and dissociation of Lanthanide(III)-DOTA complexes. Inorg Chem 33 (1994) 4070-4076
23. Stimmel J.B., and Kull F.C. Samarium-153 and Lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. Nucl Med Biol 25 (1998) 117-125
24. Hu F., Cutler C.S., Hoffman T., Sieckmen G., Volkert W.A., and Jurisson S.S. Pm-149 DOTA bombesin analogs for potential radiotherapy. In vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-βAla-BBN(7-14)NH2. Nucl Med Biol 29 (2002) 423-430
25. 177Lu-Labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47 (2006) 1144-1152
26. Panigone S., and Nunn A.D. Lutetium-177 labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging 5 4 (2006) 310-321
27. Zhang H., Chen J., Waldherr C., Hinni K., Waser B., and Reubi J.C. Synthesis and evaluation of bombesin derivatives on the basis of Pan-Bombesin peptides labeled with Indium-111, Lutetium-177 and Yttrium-90 for targeting bombesin receptors-expressing tumors. Cancer Res 64 (2004) 6707-6715
28. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 30 (2003) 917-920
29. Schubiger P.A., Alberto R., and Smith A. Vehicles, chelators, and radionuclides: choosing the "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconjug Chem 7 (1996) 165-179
30. Moody T.W., Mantey S.A., Pradhan T.K., Schumann M., Nakagawa T., and Martinez A. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem 279 22 (2004) 23580-23589
31. Zhou J., Chen J., Zhong R., Mokotoff M., Shultz L.D., and Ball E.D. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clin Cancer Res 12 7 (2006) 2224-2231
32. Moody T.W., Sun L.C., Mantey S.A., Pradhan T., Mackey L.V., Gonzales N., et al. In vitro and in vivo antitumor effects of cytotoxic camptothecin-bombesin conjugates are mediated by specific interaction with cellular bombesin receptors. J Pharmacol Exp Ther 318 3 (2006) 1265-1272
33. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 Suppl1 (2005) 99S-106S
34. Melis M. Dose-response effect of gelofusine on renal retention of radiolabeled octreotate in rats with CA20948 tumours. Q J Nucl Med Mol Imaging 52 2, Suppl 1 (2008) 15 [19th IRIST Meeting, Krakow, Poland]
35. Breeman W.A.P., Kwekkeboom D.J., Kooij P.P.M., Bakker W.H., Hofland L.J., Visser T.J., et al. Effect on dose and specific activity on tissue distribution on indium-111-pentreotide in rats. J Nucl Med 36 (1995) 623-627
36. de Jong M., Breeman W.A., Bernard B.F., van Gameren A., de Bruin E., Bakker W.H., et al. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount. Eur J Nucl Med 26 7 (1999) 69